A Multivalent Polyomavirus Vaccine Elicits Durable Neutralizing Antibody Responses in Macaques
Preprint
Abstract
In 2019, there were about 100,000 kidney transplants globally, with more than a quarter of them performed in the United States. Unfortunately, some engrafted organs are lost to polyomavirus-associated nephropathy (PyVAN) caused by BK and JC viruses (BKPyV and JCPyV). Transplant patients are routinely monitored for BKPyV viremia, which is an accepted hallmark of nascent nephropathy. If viremia is detected, a reduction in immunosuppressive therapy is standard care, but the intervention comes with increased risk of immune rejection of the engrafted organ. Recent reports have suggested that transplant recipients with high levels of polyomavirus-neutralizing antibodies are protected against PyVAN. Virus-like particle (VLP) vaccines, similar to approved human papillomaviruses vaccines, have an excellent safety record and are known to induce high levels of neutralizing antibodies associated and long-lasting protection from infection. In this study, we demonstrate that VLPs representing BKPyV genotypes I, II, and IV, as well as JCPyV genotype 2 produced in insect cells elicit robust antibody titers. In rhesus macaques, all monkeys developed neutralizing antibody titers above a previously proposed protective threshold of 10,000. A second inoculation, administered 19 weeks after priming, boosted titers to a plateau of ≥25,000 that was maintained for almost two years. No vaccine-related adverse events were observed in any macaques. A multivalent BK/JC VLP immunogen did not show inferiority compared to the single-genotype VLP immunogens. Considering these encouraging results, we believe a clinical trial administering the multivalent VLP vaccine in patients waiting to receive a kidney transplant is warranted to evaluate its ability to reduce or eliminate PyVAN. HIGHLIGHTS Recombinant virus-like particle vaccine was safely administered to rhesus macaques Vaccination generated high-titer neutralizing antibody responses Multivalent BK/JC polyomavirus vaccine was as effective as monovalent vaccines High neutralizing titers were sustained for 92 weeks without appreciable declineKeywords
All Related Versions
- Published version: Vaccine, 41 (10), 1735.
This publication has 63 references indexed in Scilit:
- Different Serologic Behavior of MCPyV, TSPyV, HPyV6, HPyV7 and HPyV9 Polyomaviruses Found on the SkinPLOS ONE, 2013
- Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant RecipientsPLOS Pathogens, 2012
- Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor SpecificityThe Journal of Infectious Diseases, 2011
- Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsidVirology, 2010
- Quantitation of Human Seroresponsiveness to Merkel Cell PolyomavirusPLOS Pathogens, 2009
- Seroepidemiology of Human PolyomavirusesPLOS Pathogens, 2009
- Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML)PLOS Genetics, 2009
- Age-Related Urinary Excretion of BK Polyomavirus by Nonimmunocompromised IndividualsJournal of Clinical Microbiology, 2007
- Ciprofloxacin Decreased Polyoma BK Virus Load in Patients Who Underwent Allogeneic Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2005
- Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant RecipientsNew England Journal of Medicine, 2002